Please Wait
Applying Filters...
menu
    • menu
    munit-sa-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Lorundrostat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 247,857Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mineralys Reports Late-Breaking Data From Advance-HTN Trial
    Mineralys Reports Late-Breaking Data From Advance-HTN Trial

    29 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/29/3051760/0/en/Mineralys-Therapeutics-Announces-Late-Breaking-Data-from-Advance-HTN-Pivotal-Trial-of-Lorundrostat-in-Uncontrolled-and-Resistant-Hypertension-Presented-at-the-American-College-of-C.html

    GLOBENEWSWIRE
    29 Mar 2025
    Share Share
    Mineralys Reports Positive Ph3 Lorundrostat Data In Hypertension
    Mineralys Reports Positive Ph3 Lorundrostat Data In Hypertension

    10 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/10/3039559/0/en/Mineralys-Therapeutics-Announces-Positive-Topline-Results-from-Launch-HTN-and-Advance-HTN-Pivotal-Trials-of-Lorundrostat-for-the-Treatment-of-Uncontrolled-or-Resistant-Hypertension.html

    GLOBENEWSWIRE
    10 Mar 2025
    Share Share
    Mineralys Completes Enrollment in Explore-CKD Ph 2 for Hypertension
    Mineralys Completes Enrollment in Explore-CKD Ph 2 for Hypertension

    04 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/04/3020225/0/en/Mineralys-Therapeutics-Completes-Enrollment-in-Explore-CKD-Phase-2-Trial-of-Lorundrostat-for-the-Treatment-of-Hypertension-in-Subjects-with-Stage-2-to-3b-CKD-and-Albuminuria.html

    GLOBENEWSWIRE
    04 Feb 2025
    Share Share
    Mineralys Completes Enrollment in Lorundrostat Hypertension Trial
    Mineralys Completes Enrollment in Lorundrostat Hypertension Trial

    30 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/30/2971654/0/en/Mineralys-Therapeutics-Completes-Enrollment-Ahead-of-Schedule-in-Launch-HTN-the-Second-Pivotal-Trial-of-Lorundrostat-for-the-Treatment-of-Hypertension.html

    GLOBENEWSWIRE
    30 Oct 2024
    Share Share
    Mineralys Therapeutics Completes Enrollment In Advance-HTN Trial
    Mineralys Therapeutics Completes Enrollment In Advance-HTN Trial

    25 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/25/2952886/0/en/Mineralys-Therapeutics-Completes-Target-Enrollment-in-Pivotal-Advance-HTN-Trial-of-Lorundrostat-for-the-Treatment-of-Hypertension.html

    GLOBENEWSWIRE
    25 Sep 2024
    Share Share
    Mineralys Presents Post-Hoc Analysis from Target-HTN Phase 2 of Lorundrostat
    Mineralys Presents Post-Hoc Analysis from Target-HTN Phase 2 of Lorundrostat

    02 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/02/2772515/0/en/Mineralys-Therapeutics-Presents-New-Post-Hoc-Analysis-from-Target-HTN-Phase-2-Trial-of-Lorundrostat-in-Late-Breaking-Poster-Session-at-ASN-Kidney-Week-2023-Meeting.html

    GLOBENEWSWIRE
    02 Nov 2023
    Share Share